Related references
Note: Only part of the references are listed.Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A
Karen L. Reckamp et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Immune Evasion Mechanism and AXL
Hye-Youn Son et al.
FRONTIERS IN ONCOLOGY (2021)
Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update.
Lauren Averett Byers et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
Naoko Okura et al.
CLINICAL CANCER RESEARCH (2020)
Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLC
E. Felip et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer
Feng Wang et al.
TRANSLATIONAL CANCER RESEARCH (2019)
Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers
Emily N. Arner et al.
FRONTIERS IN ONCOLOGY (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS
Sonja Loges et al.
BLOOD (2018)
Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models
Zhiqiang Guo et al.
ONCOTARGET (2017)
Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer
Jian-Zhong Lin et al.
ONCOTARGET (2017)
Axl Receptor Axis: A New Therapeutic Target in Lung Cancer
Pavel A. Levin et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression
Katsuaki Sato et al.
PLOS ONE (2016)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Catherine Wilson et al.
CANCER RESEARCH (2014)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al.
LANCET (2014)
Higher Expression of Receptor Tyrosine Kinase Axl, and Differential Expression of its Ligand, Gas6, Predict Poor Survival in Lung Adenocarcinoma Patients
Masashi Ishikawa et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Oxidative stress enhances Axl-mediated cell migration through an Akt1/Rac1-dependent mechanism
Jhy-Shrian Huang et al.
FREE RADICAL BIOLOGY AND MEDICINE (2013)
The sva package for removing batch effects and other unwanted variation in high-throughput experiments
Jeffrey T. Leek et al.
BIOINFORMATICS (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer
Sacha J. Holland et al.
CANCER RESEARCH (2010)
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
Rachel Ma Linger et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Expression of Axl in lung adenocarcinoma and correlation with tumor progression
YS Shieh et al.
NEOPLASIA (2005)
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel
SD Baker et al.
CLINICAL CANCER RESEARCH (2004)
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
FA Shepherd et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
